Reactions 1680, p270 - 2 Dec 2017
Acquired resistance to osimertinib: case report
In a study of 86 patients, a patient [age and sex not stated]
was described, who acquired resistance to osimertinib during
treatment of a non-small-cell lung carcinoma [route, dosage
and duration of treatment to reaction onset not stated]. The
patient, who had T790M-positive non-small-cell lung
carcinoma, started receiving treatment with osimertinib.
Subsequently, a serial plasma genotyping confirmed the
acquired KRAS Q61K mutation on osimertinib therapy
[outcome not stated].
Author comment: "The remaining 11 [patients] had loss of
T790M, of whom 5 had evidence of a competing resistance
mechanism: 2 with histologic transformation to SCLC, one
with BRAF V600E, one with an FGFR3-TACC fusion, and one
with KRAS Q61K." "For the final case, we confirmed the
acquired KRAS Q61K on therapy using serial plasma
Oxnard GR, et al. Overgrowth of competing resistance mechanisms, such as an
acquired KRAS mutation, underlies a poor prognosis subtype of acquired
resistance to osimertinib in T790M-positive NSCLC. Cancer Research 77 (Suppl.
1): abstr. 4112, No. 13, Jul 2017. Available from: URL: http://
doi.org/10.1158/1538-7445.AM2017-4112 [abstract] - USA
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved